Commonly, in SCLC, patients are treated with systemic therapy using cisplatin or carboplatin and in extensive-stage SCLC, NCCN guidelines recommend the combination of chemotherapy and immunotherapy targeting PD-L1 (atezolizumab or durvalumab). Here, CD274 is linked to small cell lung carcinoma.